TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) Free cash flow 2016–2025
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$103.2MFY2025 · since FY2016: -$37.4M → -$103.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$103.2M | -69.1% |
| FY2024 | -$61.0M | +44.5% |
| FY2023 | -$109.9M | +24.8% |
| FY2022 | -$146.2M | -31.9% |
| FY2021 | -$110.9M | -94.1% |
| FY2020 | -$57.1M | -114.0% |
| FY2019 | -$26.7M | -11.4% |
| FY2018 | -$24.0M | -25.3% |
| FY2017 | -$19.1M | +48.8% |
| FY2016 | -$37.4M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More TNXP financial trends
TNXP RevenueTNXP Net incomeTNXP Net marginTNXP Gross profitTNXP Gross marginTNXP Operating incomeTNXP Operating marginTNXP Operating cash flowTNXP Capital expendituresTNXP Return on equityTNXP Stock buybacksTNXP Dividends paidTNXP Total assetsTNXP Total liabilitiesTNXP Shareholders’ equityTNXP overview →